Eli Lilly and Co. (LLY) announced that its Ebglyss monotherapy monthly injection demonstrated sustained and deep responses in patients with moderate-to-severe atopic dermatitis over three years.
Findings from the ADjoin long-term extension study will be presented at the American Academy of Dermatology Annual Meeting from March 7-11 in Orlando.
Among patients receiving a once-monthly maintenance dose, 50 percent achieved complete skin clearance, while 87 percent maintained almost-clear skin at three years. Most patients did not require additional topical treatments. Ebglyss, an interleukin-13 inhibitor, continues to show a consistent safety profile with no new safety concerns, the company said.
LLY is currently trading at $905.91 down 0.75 percent or $6.85 on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.